<DOC>
	<DOCNO>NCT01280643</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin calcium , oxaliplatin , capecitabine , irinotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give drug different combination may kill tumor cell . Monoclonal antibody , bevacizumab cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving combination chemotherapy together bevacizumab cetuximab may kill tumor cell . PURPOSE : To evaluate use standard ( KRAS ) experimental ( thymidine phosphorylase , ERCC1 BRAF ) tumor test aid select chemotherapy regimen</brief_summary>
	<brief_title>Combination Chemotherapy Cetuximab Bevacizumab Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate feasibility , define completion three specific marker assay generation clinically meaningful endpoint , select treatment regimen component base biologic tumor characteristic chemotherapy-na√Øve patient metastatic colorectal cancer . SECONDARY OBJECTIVES : I . To investigate response rate associate genotype/phenotype guide therapy use Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . II . To investigate time failure treatment strategy associate genotype/phenotype guide therapy , define time initiation investigational treatment strategy death , disease progression , initiation new therapeutic agent , disease progression partial complete treatment holiday . III . To investigate progression-free survival associate genotype/phenotype guide therapy , define time enrollment time progression disease death . OUTLINE : Patients assign treatment group base marker assay result . ARM A : TP-/uncertain , KRAS BRAF wild-type , ERCC1 high ARM B : TP-/uncertain , KRAS BRAF wild-type , ERCC1 low/uncertain ARM C : TP-/uncertain , KRAS BRAF mutant/uncertain , ERCC1 high ARM D : TP-/uncertain , KRAS BRAF mutant/uncertain , ERCC1 low/uncertain ARM E : TP+ , KRAS BRAF wild-type , ERCC1 high ARM F : TP+ , KRAS BRAF wild-type , ERCC1 low/uncertain ARM G : TP+ , KRAS BRAF mutant/uncertain , ERCC1 high ARM H : TP+ , KRAS BRAF mutant/uncertain , ERCC1 low/uncertain ARM I : TP uninterpretable , KRAS BRAF uninterpretable , ERCC1 uninterpretable KRAS test standard care patient metastatic colorectal cancer ; tymidine phosphorylase , ERCC1 BRAF test assay still experimental . Courses arm A-D arm I repeat every 28 day course arm E-H repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients must histologically confirm colon rectal cancer metastasize ; biopsy metastatic site ( ) require presentation consistent metastatic disease Available archive tissue block slide primary colon rectal cancer ; approximately 25 slide primary tumor tissue necessary test marker Patients must measurable disease RECIST 1.1 , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; = 10 mm compute tomography ( CT ) scan clinical exam caliper ; lymph node must 15 mm short dimension measure CT scan Patients may receive prior therapy metastatic colorectal cancer ; prior adjuvant therapy ( include study agent ) permit complete &gt; 6 month initial detection metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin = &lt; 2 X institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) / alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase [ SGPT ] ) = &lt; 3 X institutional ULN = &lt; 5 X ULN know liver metastasis Creatinine clearance &gt; = 50 mL/min ( calculate Cockroft Gault formula ) Urine protein : creatinine ( UPC ) ratio &lt; 1.0 screening ( calculated urine protein concentration urine creatinine concentration ) ; patient UPC ratio &gt; = 1 undergo 24hour urine collection , must adequate demonstrate &lt; 1 gram order participate Ability understand willingness sign write informed consent document Patients previous chemotherapy metastatic colorectal cancer Uncontrolled hypertension ( &gt; 150/100 mmHg ) despite stable regimen antihypertensive medication History cardiovascular disease , define previous myocardial infarction , cerebrovascular accident , uncontrolled congestive heart failure ( New York Heart Association &gt; Class II ) , clinically significant ventricular arrhythmia require medication , clinically significant peripheral vascular disease , unstable angina within 6 month study enrollment Underlying neuropathy &gt; = grade 2 Serious nonhealing wound , ulcer , fistula Major surgery , open biopsy , major traumatic injury within 28 day registration , anticipation need surgical procedure course study , core biopsy fine needle aspiration within 7 day registration ; close biopsy access port placement acceptable A history thrombotic hemorrhagic disorder ; patient elevate international normalized ratio ( INR ) ( 2.0 3.0 ) stable dos therapeutic anticoagulation eligible Untreated brain metastasis ; patient treat brain metastasis complete radiation therapy , clinically radiographically stable , steroid therapy may enrol History allergic reaction attribute compound similar chemical biologic composition cetuximab , oxaliplatin , capecitabine , agent use study Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude ; breastfeed discontinue mother treated chemotherapy Human Immunodeficiency Virus ( HIV ) positive patient combination antiretroviral therapy ineligible ; appropriate study undertake patient receive combination antiretroviral therapy indicate Patients must history another neoplasm &lt; 5 year prior enrollment , except nonmetastatic , nonmelanoma skin cancer carcinoma situ cervix Patients childbearing potential unwilling unable utilize contraceptive measure include barrier contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage IVA colon cancer</keyword>
	<keyword>stage IVA rectal cancer</keyword>
	<keyword>stage IVB colon cancer</keyword>
	<keyword>stage IVB rectal cancer</keyword>
</DOC>